New antibody drug to boost COVID fight
3 years ago

New antibody drug to boost COVID fight

China Daily  

chinadaily.com.cn| Updated :2021-12-24 Editor's Note: The eyes of the world are turning to China. Nearly two years after the COVID-19 outbreak, China has granted emergency approval for its first antibody combination therapy for COVID-19 treatment, adding a tool to the world's arsenal against the disease. In an exclusive interview with China Daily, Zhang Linqi, leader of the research team and director of the Global Health and Infectious Diseases Research Center and Comprehensive AIDS Research Center at the Tsinghua University's School of Medicine, shared with us the story behind the latest breakthrough in the fight against COVID-19. The following are excerpts from the interview: Zhang Linqi, leading scientist in developing China's first approved COVID-19 antibody drug, demonstrates a model of protein on the surface of the novel coronavirus. Zhang Linqi, leading scientist in developing China's first approved COVID-19 antibody drug, talks with China Daily reporter Du Juan in Beijing on Dec 20, 2021.

China Research University Therapy Covid Drug Virus Tsinghua University Antibodies Antibody Ma Chi Zhang Linqi Yan Maoqiang Linqi  drug  covid  boost  covid19  linqi  fight  antibody  antibodies  virus  research  university  therapy  china

History of this topic

Drug giants eye China for deals despite growing Sino-US tensions
5 months ago

Drug giants eye China for deals despite growing Sino-US tensions

Hindustan Times  

* Drug giants eye China for deals despite growing Sino-US tensions Bristol Myers Squibb, Sanofi looking at China M&A -employees * AstraZeneca, Novartis have done China deals this year * Political risks are a consideration -analysts By Andrew Silver and Kane Wu SHANGHAI/HONG KONG, - Some of the biggest global drugmakers, undeterred by mounting Sino-U.S. tensions, are scouring for deals …

No new Covid variants during recent breakout in China: Lancet study
1 year, 10 months ago

No new Covid variants during recent breakout in China: Lancet study

India Today  

New coronavirus variants did not emerge during the recent outbreak of cases in China, said a study published in the medical journal, The Lancet. Samples of 350 locally acquired infections and 63 imported cases were studied during a five-week period beginning in November 2022 - shortly after China abruptly overturned its strict zero-Covid policy. Further, China also administers inactivated whole …

Amid COVID surge, China approves America’s Paxlovid, an anti-viral drug: Why this is an unlikely move
1 year, 11 months ago

Amid COVID surge, China approves America’s Paxlovid, an anti-viral drug: Why this is an unlikely move

Firstpost  

China has been reluctant to take medicines and vaccines from the West. The oral antiviral has proved to cut the risk of hospitalisation and death The recent surge in COVID-19 cases has caused China’s healthcare infrastructure to crumble. Beijing will begin distributing American pharma giant Pfizer’s drug, Paxlovid, to community health centres in the city, according to a report by …

Oral pill for COVID-19 approved by regulator
2 years, 4 months ago

Oral pill for COVID-19 approved by regulator

China Daily  

China Daily| Updated :2022-07-29 China's top drug regulator said on Monday that it has granted conditional approval for a homegrown oral pill to be used to treat COVID-19 disease, adding to the growing medical arsenal against the novel coronavirus. Azvudine, developed by the Genuine Biotech Co based in Henan province, was first conditionally approved to treat HIV-1 infected adult patients …

Production of one-dose vaccine starts in Shanghai
2 years, 10 months ago

Production of one-dose vaccine starts in Shanghai

China Daily  

A medical worker administers a booster shot of COVID-19 vaccine to a local resident at a temporary vaccination site in Beijing, Nov 29, 2021. The production of a single-shot COVID-19 vaccine made by CanSino SPH Biologics Inc, the first novel coronavirus vaccine producer in Shanghai, was launched in the city on Thursday. "The vaccine, named Convidecia, is the only single-dose …

Anti-Covid drugs potent against Omicron, antibody therapies less effective: Study
2 years, 10 months ago

Anti-Covid drugs potent against Omicron, antibody therapies less effective: Study

Deccan Chronicle  

Washington: The current drugs to treat COVID-19 remain very effective against the Omicron variant of the SARS-CoV-2 virus, according to a laboratory study. However, available antibody therapies -- typically given intravenously in hospitals -- are substantially less effective against Omicron compared to earlier variants of the virus, the researchers said. The clinically available pills and antibodies were designed and tested …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

Editor's Note: The eyes of the world are turning to China. In this ongoing series How-to China, we tell stories about how Chinese approaches promote understanding, solve problems and improve the lives of people around the globe.Nearly two years after the COVID-19 outbreak, China has granted emergency approval for its first antibody combination therapy for COVID-19 treatment, adding a tool …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

A 3D graphic representation of the novel coronavirus. Zhang: The antibody therapy is mainly used to treat patients with mild or moderate symptoms and those at a high risk of developing severe symptoms, including patients with severe underlying health problems such as diabetes and cardiovascular diseases. The antibody drug not only prevents the virus from penetrating cells, but also boosts …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

Editor's Note: The eyes of the world are turning to China. Nearly two years after the COVID-19 outbreak, China has granted emergency approval for its first antibody combination therapy for COVID-19 treatment, adding a tool to the world's arsenal against the disease. In an exclusive interview with China Daily, Zhang Linqi, leader of the research team and director of the …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

A member of the research team is seen at work. Q: Will we gain more market approvals beyond China to make greater contribution to the global battle against COVID-19? After entering the phase one clinical trial in China, we conducted phase two and phase three clinical trials in areas with high COVID-19 prevalence as the epidemic had been basically brought …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

Editor's Note: The eyes of the world are turning to China. In this ongoing series How-to China, we tell stories about how Chinese approaches promote understanding, solve problems and improve the lives of people around the globe.Nearly two years after the COVID-19 outbreak, China has granted emergency approval for its first antibody combination therapy for COVID-19 treatment, adding a tool …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

A 3D graphic representation of the novel coronavirus. Zhang: The antibody therapy is mainly used to treat patients with mild or moderate symptoms and those at a high risk of developing severe symptoms, including patients with severe underlying health problems such as diabetes and cardiovascular diseases. The antibody drug not only prevents the virus from penetrating cells, but also boosts …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

Zhang Linqi, leading scientist in developing China's first approved COVID-19 antibody drug, demonstrates a model of protein on the surface of the novel coronavirus. Q: What is the difference between China's first approved COVID-19 antibody drug and similar drugs in other countries? First, the antibodies needed to be able to identify the different locations where the virus unlocks human cells. …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

A 3D graphic representation of the novel coronavirus. After entering the phase one clinical trial in China, we conducted phase two and phase three clinical trials in areas with high COVID-19 prevalence as the epidemic had been basically brought under control in China. Zhang Linqi, leading scientist in developing China's first approved COVID-19 antibody drug, talks with China Daily reporter …

New antibody drug to boost COVID fight
3 years ago

New antibody drug to boost COVID fight

China Daily  

Editor's Note: The eyes of the world are turning to China. Nearly two years after the COVID-19 outbreak, China has granted emergency approval for its first antibody combination therapy for COVID-19 treatment, adding a tool to the world's arsenal against the disease. In an exclusive interview with China Daily, Zhang Linqi, leader of the research team and director of the …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

A member of the research team is seen at work. Q: Will we gain more market approvals beyond China to make greater contribution to the global battle against COVID-19? After entering the phase one clinical trial in China, we conducted phase two and phase three clinical trials in areas with high COVID-19 prevalence as the epidemic had been basically brought …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

Zhang Linqi, leading scientist in developing China's first approved COVID-19 antibody drug, demonstrates a model of protein on the surface of the novel coronavirus. Q: What is the difference between China's first approved COVID-19 antibody drug and similar drugs in other countries? First, the antibodies needed to be able to identify the different locations where the virus unlocks human cells. …

New antibody drug to boost COVID fight
3 years ago

New antibody drug to boost COVID fight

China Daily  

Editor's Note: The eyes of the world are turning to China. Nearly two years after the COVID-19 outbreak, China has granted emergency approval for its first antibody combination therapy for COVID-19 treatment, adding a tool to the world's arsenal against the disease. In an exclusive interview with China Daily, Zhang Linqi, leader of the research team and director of the …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

Nearly two years after the COVID-19 outbreak, China has granted emergency approval for its first antibody combination therapy for COVID-19 treatment, adding a tool to the world's arsenal against the disease. In an exclusive interview with China Daily, Zhang Linqi, leader of the research team and director of the Global Health and Infectious Diseases Research Center and Comprehensive AIDS Research …

How-to China: New antibody drug to boost COVID fight
3 years ago

How-to China: New antibody drug to boost COVID fight

China Daily  

Nearly two years after the COVID-19 outbreak, China has granted emergency approval for its first antibody combination therapy for COVID-19 treatment, adding a tool to the world's arsenal against the disease. In an exclusive interview with China Daily, Zhang Linqi, leader of the research team and director of the Global Health and Infectious Diseases Research Center and Comprehensive AIDS Research …

Pfizer Pill Becomes First US-authorized Home Covid-19 Treatment
3 years ago

Pfizer Pill Becomes First US-authorized Home Covid-19 Treatment

News 18  

U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus. The long-awaited milestone comes as U.S. cases, hospitalizations and deaths are all rising and health officials warn of a tsunami of new infections from the omicron variant that …

New COVID-19 antibody drug OK’d to protect most vulnerable
3 years ago

New COVID-19 antibody drug OK’d to protect most vulnerable

LA Times  

This image provided by AstraZeneca shows packaging and vials for the company’s Evusheld medication. Federal health officials on Wednesday authorized a COVID-19 antibody drug for people with serious health problems or allergies who can’t get adequate protection from vaccination. People who could benefit from the antibody drug include cancer patients, organ transplant recipients and people taking immune-suppressing drugs for conditions …

New antiviral drugs are coming for COVID. Here's what you need to know
3 years ago

New antiviral drugs are coming for COVID. Here's what you need to know

NPR  

New antiviral drugs are coming for COVID. Given the higher efficacy of the antibody treatments, "I think we will continue to use those, particularly for high risk people," says Dr. Rajesh Gandhi, an infectious diseases physician at Massachusetts General Hospital and Harvard Medical School who serves on COVID-19 Treatment Guidelines Panels for the NIH and the Infectious Diseases Society of …

Merck’s Molnupiravir, Glenmark’s Nasal Spray, Zydus' Antibody Cocktail: 20+ Drugs in Pipeline for Covid
3 years, 2 months ago

Merck’s Molnupiravir, Glenmark’s Nasal Spray, Zydus' Antibody Cocktail: 20+ Drugs in Pipeline for Covid

News 18  

Merck’s Molnupiravir, Zydus’ antibody cocktail and Glenmark’s nasal spray are among more than 20 new drugs in different stages of drug trials or approvals in India to treat Covid-19. “As the world needs Covid-19 vaccines, the world also needs proven and effective Covid-19 therapies,” Lahariya said. List of Drugs in the Pipeline US pharma giant Merck and Ridgeback Biotherapeutics’ oral …

Regeneron: Covid-19 antibody treatments work, but they’re ‘not the path out of this pandemic’
3 years, 4 months ago

Regeneron: Covid-19 antibody treatments work, but they’re ‘not the path out of this pandemic’

CNN  

CNN — When Texas Gov. Monoclonal antibodies such as those made by Regeneron and GlaxoSmithKline won’t work for every Covid-19 patient; mAbs, as they are known, are only available for people age 12 and older and who aren’t hospitalized or severely ill. Regeneron’s therapy can also be used for some people who know they were exposed to the virus,but don’t …

Patients unable to produce Covid antibodies supported by new drug
3 years, 4 months ago

Patients unable to produce Covid antibodies supported by new drug

NL Times  

The Erasmus Medical Center has begun using the drug REGEN-Cov to treat patients with Covid-19 who have a reduced ability to produce antibodies themselves. “You are buying time for patients to make their own antibodies”, said Bart Rijnders, an internist and infectious diseases specialist at the hospital. “In patients who will never produce their own antibodies, it helps the other …

Vaccines are terrific, but where are the COVID-19 treatments?
3 years, 5 months ago

Vaccines are terrific, but where are the COVID-19 treatments?

LA Times  

Since the early days of the pandemic, we’ve all wanted to know when and how it will end. That research has yielded three authorized vaccines — so far — that are highly effective not just against the original virus but also against its many variants, including the highly transmissible Delta variant. Mehta spoke to The Times about which medicines are …

US to spend $3.2B on treatments for COVID-19, other viruses
3 years, 6 months ago

US to spend $3.2B on treatments for COVID-19, other viruses

Associated Press  

WASHINGTON — The United States is devoting $3.2 billion to speed development of antiviral pills to treat COVID-19 and other dangerous viruses that could turn into pandemics. The new program will invest in “accelerating things that are already in progress” for COVID-19 but also would work to come up with treatments for other viruses, said Dr. Anthony Fauci, the nation’s …

U.S. to spend $3.2 billion on treatments for COVID-19 and other viral diseases
3 years, 6 months ago

U.S. to spend $3.2 billion on treatments for COVID-19 and other viral diseases

LA Times  

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, speaks May 11 at a hearing on Capitol Hill. The new program will invest in “accelerating things that are already in progress” for COVID-19 but also would work to come up with treatments for other viral conditions, said Dr. Anthony Fauci, the nation’s top infectious disease expert. …

Monoclonal antibody treatment for COVID-19 could be a game changer
3 years, 6 months ago

Monoclonal antibody treatment for COVID-19 could be a game changer

The Hindu  

Monoclonal antibody treatment is now seen as a relatively effective and safer alternative in treating COVID-19 patients, with doctors stating that, as with any other drug, timing is very important for the administration of the therapy that’s touted as a game changer. “Monoclonal antibody treatment could prove to be a game changer in times to come if used at the …

Clinical Trials on Nasal Spray Covid-19 Vaccine Underway in China: Report
3 years, 6 months ago

Clinical Trials on Nasal Spray Covid-19 Vaccine Underway in China: Report

News 18  

China is conducting clinical trials on an inhaled coronavirus vaccine that is being developed jointly by the Institute of Military Medicine under the Academy of Military Sciences, affiliated to the People’s Liberation Army, and China’s CanSino Biologics. After collecting the data, experts will study the safety and effectiveness of the inhaled vaccine, a modified version of an injectable adenovirus vector …

Nasal spray designed from engineered antibody could treat Covid-19, boost efficacy: Report
3 years, 6 months ago

Nasal spray designed from engineered antibody could treat Covid-19, boost efficacy: Report

India Today  

As the second wave of Covid-19 recedes, countries are rushing to vaccinate their people to protect vulnerable groups with some experts anticipating a third wave of the pandemic. A study published in journal Nature stated that nasal spray of a designer antibody offers strong protection against variants of coronavirus in mice. The engineered antibody managed to reduce the amount of …

China authorises CoronaVac COVID-19 vaccine for children above 3 years
3 years, 6 months ago

China authorises CoronaVac COVID-19 vaccine for children above 3 years

Deccan Chronicle  

Beijing: China has authorised the emergency use of CoronaVac, a COVID-19 vaccine manufactured by Chinese firm Sinovac, for children aged between 3 and 17 years, Sinovac Chairman Yin Weidong said. Sinovac has finished the Phrase I and II clinical research stage, involving several hundred volunteers in this age group, which has proved that the vaccine is as safe and efficient …

China authorises CoronaVac Covid-19 vaccine for children above 3 years
3 years, 6 months ago

China authorises CoronaVac Covid-19 vaccine for children above 3 years

India Today  

China has authorised the emergency use of CoronaVac, a Covid-19 vaccine manufactured by Chinese firm Sinovac, for children aged between 3 and 17 years, Sinovac Chairman Yin Weidong said. Sinovac has finished the phase I and II clinical research stage, involving several hundred volunteers in this age group, which has proved that the vaccine is as safe and efficient as …

WHO approves emergency use of China's CoronaVac vaccine
3 years, 6 months ago

WHO approves emergency use of China's CoronaVac vaccine

India TV News  

The World Health Organisation on Tuesday approved the Chinese COVID-19 vaccine CoronaVac for emergency use, the second Chinese vaccine to receive the global health body's green light. "The world desperately needs multiple COVID-19 vaccines to address the huge access inequity across the globe," said Dr. Mariangela Simao, WHO assistant-director general for Access to Health Products. "The efficacy results showed that …

The science behind China's Sinovac vaccine: How does CoronaVac fight Covid-19
3 years, 6 months ago

The science behind China's Sinovac vaccine: How does CoronaVac fight Covid-19

India Today  

The World Health Organisation on Tuesday granted emergency usage approval to the Sinovac-CoronaVac vaccine developed by China stating that it meets the international standards for safety, efficacy and manufacturing. "Vaccine efficacy results showed that it prevented symptomatic disease in 51 per cent of those vaccinated and prevented severe Covid-19 and hospitalisation in 100 per cent of the studied population," WHO …

Zydus Cadila seeks human trial approval for Covid-19 antibody cocktail
3 years, 6 months ago

Zydus Cadila seeks human trial approval for Covid-19 antibody cocktail

India Today  

Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild Covid-19, as the country grapples with a shortage of medicines and vaccines needed to effectively tackle a devastating second wave of the pandemic. READ: Covid Antibody Cocktail will reduce hospitalisation, can be given to children: Dr Naresh Trehan The therapy is a cocktail of …

Antibody cocktail to treat Covid-19 now in India. What is it? Who should take the therapy?
3 years, 6 months ago

Antibody cocktail to treat Covid-19 now in India. What is it? Who should take the therapy?

India Today  

An 84-year-old man from Haryana, who was the first Covid-19 patient in India to receive an antibody drug cocktail authorised by the Centre earlier this month, has been discharged from hospital. The antibody cocktail shot into the limelight after it was used to treat former United States President Donald Trump last year. The antibody cocktail is to be administered for …

EU regulator begins reviewing China’s Sinovac COVID-19 vaccine
3 years, 7 months ago

EU regulator begins reviewing China’s Sinovac COVID-19 vaccine

Al Jazeera  

The first step towards possible approval comes after studies suggested the shot produces an immune response against coronavirus. The European Union’s medicines regulator has started a rolling review of the COVID-19 vaccine produced by Chinese pharmaceutical company Sinovac to assess its effectiveness and safety, marking the first step towards its possible approval for use in the 27-nation bloc. The agency …

China mulls mixing vaccines to improve efficacy of jabs
3 years, 8 months ago

China mulls mixing vaccines to improve efficacy of jabs

India Today  

China is considering the mixing of different Covid-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert has told a conference. His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country's vaccines, as China forges ahead in its mass vaccination campaign and exports …

Coronavirus Today: The threat of viral variants
3 years, 10 months ago

Coronavirus Today: The threat of viral variants

LA Times  

I’m Amina Khan, and it’s Tuesday, Feb. 2. “Age is not only efficient, it’s easy for the vaccination sites to confirm.” In other news, state corrections officials ignored the warnings of front-line health workers and pressured them to transfer 189 potentially coronavirus-infected people incarcerated in a Chino men’s prison to San Quentin State Prison last May — triggering a deadly …

China Says 16 Covid-19 Vaccines Undergoing Clinical Trials, Seven in Phase 3
3 years, 10 months ago

China Says 16 Covid-19 Vaccines Undergoing Clinical Trials, Seven in Phase 3

News 18  

As the demand for the COVID-19 vaccine intensified around the world, China said that it has increased the number of vaccines undergoing clinical trials to 16 from 11 to step up supplies at home and abroad. Yang Sheng, Deputy Director of China’s National Medical Products Administration’s drug registration bureau, said last month that a total of 11 Chinese vaccine candidates …

China’s Sinovac vaccine trial results far less effective than initially claimed in Brazil
3 years, 11 months ago

China’s Sinovac vaccine trial results far less effective than initially claimed in Brazil

CNN  

CNN — A leading Chinese Covid-19 vaccine developed by Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of Sao Paulo Tuesday. Silvio Avila/AFP/Getty Images Analysts said the efficacy rate of Sinovac’s Coronavac vaccinein Brazil – the lowest among its global competitors – could …

UK Scientists Trial Instant Immunity Antibody Drug Treatment for Coronavirus
3 years, 11 months ago

UK Scientists Trial Instant Immunity Antibody Drug Treatment for Coronavirus

News 18  

Scientists in the UK have begun trials of innovative antibody drug treatments that they hope could provide instant protection against COVID-19. The University College London Hospitals NHS Trust said that the researchers in the Storm Chase study believe a Long Acting AntiBody known as AZD7442, developed by AstraZeneca, may offer immediate and long-term protection to people who have been recently …

Low Demand For Antibody Drugs Against COVID-19
4 years ago

Low Demand For Antibody Drugs Against COVID-19

NPR  

Low Demand For Antibody Drugs Against COVID-19 Enlarge this image toggle caption Alex Brandon/AP Alex Brandon/AP Federal officials are disappointed to find that the monoclonal antibody drugs they've shipped across the country aren't being used rapidly. Kumar says, ideally, nurses would be sent to people's homes for treatment, "but that itself is a challenge because we are so constrained right …

China's Sinovac Aims for 600 Million Dose Capacity for Covid-19 Vaccine
4 years ago

China's Sinovac Aims for 600 Million Dose Capacity for Covid-19 Vaccine

News 18  

Chinese vaccine company Sinovac announced Monday that it is planning to complete a new facility to double its annual vaccine production capacity to 600 million doses by the end of the year, while also securing a $500 million investment in a boost to its COVID-19 vaccine development efforts. China has at least five COVID-19 vaccine candidates running late stage clinical …

Chinese Covid-19 vaccine maker gets $500 million funding boost
4 years ago

Chinese Covid-19 vaccine maker gets $500 million funding boost

Deccan Chronicle  

BEIJING: Chinese pharmaceutical firm Sinovac Biotech has secured half a billion dollars in extra funding to produce its Covid-19 vaccine, it said Monday, as the country races to roll out a jab for general use. Sino Biopharmaceutical Limited, a Hong Kong-listed medical research firm, said on Monday that it will invest $515 million for the development and production of CoronaVac, …

Chinese Covid-19 Vaccine Candidate Appears Safe, Induces Immune Response, Preliminary Study Finds
4 years, 1 month ago

Chinese Covid-19 Vaccine Candidate Appears Safe, Induces Immune Response, Preliminary Study Finds

News 18  

Results from an early-phase clinical trial of a Chinese vaccine candidate, CoronaVac, revealed that the formulation appears safe and induces an antibody response in healthy volunteers aged 18 to 59 years. According to the findings of the phase 1/2 randomised clinical trial, published in The Lancet Infectious Diseases journal, the vaccine candidate could induce an antibody response in participants within …

Coronavirus: US 'not ready for antibody drugs', say Harvard doctors
4 years, 1 month ago

Coronavirus: US 'not ready for antibody drugs', say Harvard doctors

Daily Mail  

Two doctors are expressing their concerns about the Trump administration's plans to quickly roll out coronavirus antibody treatments. It comes just two days after the US Food and Drug Administration approved Eli Lilly's monoclonal antibody treatment for emergency use authorization on Monday, with plans to roll it out as early as this week. Two Harvard doctors wrote an editorial expressing …

Discover Related